OIA response: special authority approvals for adalimumab, etanercept, secukinumab, infliximab, tocilizumab, rituximab

Information relating to the initiations and renewals by indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by quarter from January 2020 to September 2020.

27 November 2020

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Thank you for your request dated 30 October 2020 under the Official Information Act 1982 (OIA) for information relating to Special Authority approvals data for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab. You asked for:

Nationwide Special Authority [approved] initiations and renewals by indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by quarter from January 2020 to September 2020.

Please find the requested data (and associated notes/caveats) for approved applications attached with this response. As requested, this data has been prepared by quarter (Q1 2020 = January-March, Q2 = April-June, Q3 2020 = July-September).

Special authority data for adalimumab, etanercept, secukinumab, tocilizumab and rituximab. [XLSX, 23 KB]

Please note that PHARMAC approaches its assessment of requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).

We have made some adjustments to the data provided where total applications are equal to or less than 10 (displayed as <10) as we consider this is necessary to protect the privacy of those patients (section 9(2)(a)).

As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.

Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

Yours sincerely 

Rachel Read
Manager, Policy and Government Services